Drug1st-line biologic line

Omalizumab

Anti-IgE monoclonal antibody

Response rate
Significant NPS reduction
Onset
4–8 weeks
Route
SC every 2–4 weeks (dose by IgE/weight)
Line
1st-line biologic
IgM effect
Reduces polyp score
Evidence level
green

Evidence summary

Binds free IgE, preventing mast cell/basophil activation. POLYP 1 and POLYP 2 trials showed significant NPS improvement, reduced congestion, and improved SNOT-22. FDA-approved 2020 for CRSwNP. May be preferred in patients with high IgE and comorbid allergic asthma.

Molecular targets

MoleculeRoleExpressionEvidence
IgEAllergic effector immunoglobulinElevated (local and systemic)established

Sources (2)

T2Gevaert P et al. (2020) Efficacy and safety of omalizumab in nasal polyposis: POLYP 1 and POLYP 2 trialsDOI ↗
T5Fokkens WJ et al. (2020) EPOS/EUFOREA 2020 treatment algorithm for CRSwNPDOI ↗